US Bancorp DE Acquires 316 Shares of argenx SE (NASDAQ:ARGX)

US Bancorp DE raised its stake in shares of argenx SE (NASDAQ:ARGX) by 7.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,350 shares of the company’s stock after purchasing an additional 316 shares during the quarter. US Bancorp DE’s holdings in argenx were worth $2,358,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of ARGX. J.Safra Asset Management Corp increased its position in shares of argenx by 590.0% during the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock worth $30,000 after purchasing an additional 59 shares in the last quarter. Blue Trust Inc. grew its stake in argenx by 620.0% during the second quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after buying an additional 62 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of argenx by 51.3% during the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after buying an additional 40 shares in the last quarter. Cromwell Holdings LLC increased its holdings in shares of argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after buying an additional 66 shares in the last quarter. Finally, Point72 Hong Kong Ltd bought a new position in shares of argenx in the second quarter valued at approximately $76,000. 60.32% of the stock is currently owned by institutional investors.

argenx Price Performance

Shares of NASDAQ:ARGX opened at $588.97 on Thursday. The company has a market capitalization of $35.22 billion, a price-to-earnings ratio of -669.28 and a beta of 0.61. The firm’s 50 day simple moving average is $544.00 and its 200 day simple moving average is $471.34. argenx SE has a fifty-two week low of $327.73 and a fifty-two week high of $611.22.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $588.88 million for the quarter, compared to analysts’ expectations of $543.29 million. During the same period last year, the firm posted ($1.25) earnings per share. Equities research analysts expect that argenx SE will post -0.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

ARGX has been the topic of a number of research analyst reports. Citigroup increased their price target on argenx from $512.00 to $635.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Oppenheimer raised their target price on argenx from $560.00 to $646.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. HC Wainwright lifted their price target on argenx from $533.00 to $617.00 and gave the company a “buy” rating in a report on Friday, November 1st. Guggenheim increased their price objective on shares of argenx from $585.00 to $665.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Finally, JMP Securities boosted their target price on shares of argenx from $497.00 to $606.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Four research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, argenx has an average rating of “Moderate Buy” and an average price target of $615.50.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.